世界のヒストプラズマ症治療市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV12199)
◆英語タイトル:Global Histoplasmosis Treatment Market Size, Status and Forecast 2020-2026
◆商品コード:QYR20NV12199
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:98
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートはヒストプラズマ症治療の世界市場について調査・分析した資料です。種類別(アムホテリシンB、イトラコナゾール、ケトコナゾール、その他)の市場規模、用途別(病院薬局、民間クリニック、ドラッグストア・小売薬局、Eコマース)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別ヒストプラズマ症治療の競争状況、市場シェア
・世界のヒストプラズマ症治療市場:種類別市場規模 2015年-2020年(アムホテリシンB、イトラコナゾール、ケトコナゾール、その他)
・世界のヒストプラズマ症治療市場:種類別市場規模予測 2021年-2026年(アムホテリシンB、イトラコナゾール、ケトコナゾール、その他)
・世界のヒストプラズマ症治療市場:用途別市場規模 2015年-2020年(病院薬局、民間クリニック、ドラッグストア・小売薬局、Eコマース)
・世界のヒストプラズマ症治療市場:用途別市場規模予測 2021年-2026年(病院薬局、民間クリニック、ドラッグストア・小売薬局、Eコマース)
・北米のヒストプラズマ症治療市場分析:米国、カナダ
・ヨーロッパのヒストプラズマ症治療市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアのヒストプラズマ症治療市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米のヒストプラズマ症治療市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカのヒストプラズマ症治療市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Bristol Myers Squibb、Sigma tau pharmaceuticals Inc.、Three rivers pharmaceuticals、Astellas pharma US Inc.、Abbott laboratories、Abraxis pharmaceutical products、Teva parenteral medicines Inc.、X gen pharmaceuticals Inc.
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Histoplasmosis is an infection that occurs from breathing spores of a fungus called Histoplasma capsulatum. Histoplasmosis is a fungal infection that occurs throughout the world. Histoplasma fungus grows as a mold in the soil. The soil that contains the droppings of bat or birds usually contains large amount of this fungus. The people with weakened immune system are usually more prone and increases the risk of being affected or reactivated with histoplasmosis. Usually people very young, old people and people affected with cancer, AIDS or organ transplant have severe symptoms. The people with chronic lung disease such as bronchiectasis or emphysema have high risk of severe pain. The common symptoms of histoplasmosis is fever, chills, cough, chest pain, red skin bumps, mouth sores etc. In some patients suffering from histoplasmosis may spread throughout the body and cause irritation and swelling in response to infection.
Certain symptoms also includes chest pain from swelling in lining of heart, neck stiffness etc. The disease is usually diagnosed with biopsy of lungs, skin, liver or bone marrow. Certain blood and urine test also help in detection histoplasmosis proteins or antibodies of the fungus in body. In some cases doctors also perform Chest CT scan, Chest X-ray, Bronchoscopy etc.

Market Analysis and Insights: Global Histoplasmosis Treatment Market
The global Histoplasmosis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Histoplasmosis Treatment Scope and Market Size
Histoplasmosis Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Histoplasmosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Bristol Myers Squibb
Sigma tau pharmaceuticals Inc.
Three rivers pharmaceuticals
Astellas pharma US Inc.
Abbott laboratories
Abraxis pharmaceutical products
Teva parenteral medicines Inc.
X gen pharmaceuticals Inc.

Market segment by Type, the product can be split into
Amphotericin B
Itraconazole
Ketoconazole
Other
Market segment by Application, split into
Hospitals Pharmacies
Private clinics
Drug stores and retail pharmacy
E-commerce

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Histoplasmosis Treatment Revenue
1.4 Market by Type
1.4.1 Global Histoplasmosis Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Amphotericin B
1.4.3 Itraconazole
1.4.4 Ketoconazole
1.4.5 Other
1.5 Market by Application
1.5.1 Global Histoplasmosis Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospitals Pharmacies
1.5.3 Private clinics
1.5.4 Drug stores and retail pharmacy
1.5.5 E-commerce
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Histoplasmosis Treatment Market Perspective (2015-2026)
2.2 Global Histoplasmosis Treatment Growth Trends by Regions
2.2.1 Histoplasmosis Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Histoplasmosis Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Histoplasmosis Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Histoplasmosis Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Histoplasmosis Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Histoplasmosis Treatment Players by Market Size
3.1.1 Global Top Histoplasmosis Treatment Players by Revenue (2015-2020)
3.1.2 Global Histoplasmosis Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Histoplasmosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Histoplasmosis Treatment Market Concentration Ratio
3.2.1 Global Histoplasmosis Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Histoplasmosis Treatment Revenue in 2019
3.3 Histoplasmosis Treatment Key Players Head office and Area Served
3.4 Key Players Histoplasmosis Treatment Product Solution and Service
3.5 Date of Enter into Histoplasmosis Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Histoplasmosis Treatment Historic Market Size by Type (2015-2020)
4.2 Global Histoplasmosis Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Histoplasmosis Treatment Market Size by Application (2015-2020)
5.2 Global Histoplasmosis Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Histoplasmosis Treatment Market Size (2015-2020)
6.2 Histoplasmosis Treatment Key Players in North America (2019-2020)
6.3 North America Histoplasmosis Treatment Market Size by Type (2015-2020)
6.4 North America Histoplasmosis Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Histoplasmosis Treatment Market Size (2015-2020)
7.2 Histoplasmosis Treatment Key Players in Europe (2019-2020)
7.3 Europe Histoplasmosis Treatment Market Size by Type (2015-2020)
7.4 Europe Histoplasmosis Treatment Market Size by Application (2015-2020)

8 China
8.1 China Histoplasmosis Treatment Market Size (2015-2020)
8.2 Histoplasmosis Treatment Key Players in China (2019-2020)
8.3 China Histoplasmosis Treatment Market Size by Type (2015-2020)
8.4 China Histoplasmosis Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Histoplasmosis Treatment Market Size (2015-2020)
9.2 Histoplasmosis Treatment Key Players in Japan (2019-2020)
9.3 Japan Histoplasmosis Treatment Market Size by Type (2015-2020)
9.4 Japan Histoplasmosis Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Histoplasmosis Treatment Market Size (2015-2020)
10.2 Histoplasmosis Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Histoplasmosis Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Histoplasmosis Treatment Market Size by Application (2015-2020)

11 India
11.1 India Histoplasmosis Treatment Market Size (2015-2020)
11.2 Histoplasmosis Treatment Key Players in India (2019-2020)
11.3 India Histoplasmosis Treatment Market Size by Type (2015-2020)
11.4 India Histoplasmosis Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Histoplasmosis Treatment Market Size (2015-2020)
12.2 Histoplasmosis Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Histoplasmosis Treatment Market Size by Type (2015-2020)
12.4 Central & South America Histoplasmosis Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Bristol Myers Squibb
13.1.1 Bristol Myers Squibb Company Details
13.1.2 Bristol Myers Squibb Business Overview
13.1.3 Bristol Myers Squibb Histoplasmosis Treatment Introduction
13.1.4 Bristol Myers Squibb Revenue in Histoplasmosis Treatment Business (2015-2020))
13.1.5 Bristol Myers Squibb Recent Development
13.2 Sigma tau pharmaceuticals Inc.
13.2.1 Sigma tau pharmaceuticals Inc. Company Details
13.2.2 Sigma tau pharmaceuticals Inc. Business Overview
13.2.3 Sigma tau pharmaceuticals Inc. Histoplasmosis Treatment Introduction
13.2.4 Sigma tau pharmaceuticals Inc. Revenue in Histoplasmosis Treatment Business (2015-2020)
13.2.5 Sigma tau pharmaceuticals Inc. Recent Development
13.3 Three rivers pharmaceuticals
13.3.1 Three rivers pharmaceuticals Company Details
13.3.2 Three rivers pharmaceuticals Business Overview
13.3.3 Three rivers pharmaceuticals Histoplasmosis Treatment Introduction
13.3.4 Three rivers pharmaceuticals Revenue in Histoplasmosis Treatment Business (2015-2020)
13.3.5 Three rivers pharmaceuticals Recent Development
13.4 Astellas pharma US Inc.
13.4.1 Astellas pharma US Inc. Company Details
13.4.2 Astellas pharma US Inc. Business Overview
13.4.3 Astellas pharma US Inc. Histoplasmosis Treatment Introduction
13.4.4 Astellas pharma US Inc. Revenue in Histoplasmosis Treatment Business (2015-2020)
13.4.5 Astellas pharma US Inc. Recent Development
13.5 Abbott laboratories
13.5.1 Abbott laboratories Company Details
13.5.2 Abbott laboratories Business Overview
13.5.3 Abbott laboratories Histoplasmosis Treatment Introduction
13.5.4 Abbott laboratories Revenue in Histoplasmosis Treatment Business (2015-2020)
13.5.5 Abbott laboratories Recent Development
13.6 Abraxis pharmaceutical products
13.6.1 Abraxis pharmaceutical products Company Details
13.6.2 Abraxis pharmaceutical products Business Overview
13.6.3 Abraxis pharmaceutical products Histoplasmosis Treatment Introduction
13.6.4 Abraxis pharmaceutical products Revenue in Histoplasmosis Treatment Business (2015-2020)
13.6.5 Abraxis pharmaceutical products Recent Development
13.7 Teva parenteral medicines Inc.
13.7.1 Teva parenteral medicines Inc. Company Details
13.7.2 Teva parenteral medicines Inc. Business Overview
13.7.3 Teva parenteral medicines Inc. Histoplasmosis Treatment Introduction
13.7.4 Teva parenteral medicines Inc. Revenue in Histoplasmosis Treatment Business (2015-2020)
13.7.5 Teva parenteral medicines Inc. Recent Development
13.8 X gen pharmaceuticals Inc.
13.8.1 X gen pharmaceuticals Inc. Company Details
13.8.2 X gen pharmaceuticals Inc. Business Overview
13.8.3 X gen pharmaceuticals Inc. Histoplasmosis Treatment Introduction
13.8.4 X gen pharmaceuticals Inc. Revenue in Histoplasmosis Treatment Business (2015-2020)
13.8.5 X gen pharmaceuticals Inc. Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

...

【掲載企業】

Bristol Myers Squibb、Sigma tau pharmaceuticals Inc.、Three rivers pharmaceuticals、Astellas pharma US Inc.、Abbott laboratories、Abraxis pharmaceutical products、Teva parenteral medicines Inc.、X gen pharmaceuticals Inc.

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のヒストプラズマ症治療市場2026:インサイト・予測(Global Histoplasmosis Treatment Market Size, Status and Forecast 2020-2026)]についてメールでお問い合わせはこちらでお願いします。